PTC Therapeutics | PTCT - Operating Expenses


PTC Therapeutics reported $246.3M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 266.6M 23.72M Dec/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Amgen USD 5.9B 773M Dec/2025
BioCryst Pharmaceuticals USD 146.17M 534.06M Dec/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 676.18M 131.65M Dec/2025
Cytokinetics USD 196.12M 27.43M Dec/2025
Daiichi Sankyo JPY 468.57B 15.34B Dec/2025
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Esperion Therapeutics USD 83.21M 14.06M Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
Incyte USD 1.12B 3.53B Dec/2025
Ionis Pharmaceuticals USD 418M 101.1M Dec/2025
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
Novartis USD 9.8B 61M Dec/2025
Pfizer USD 12.91B 79.89B Dec/2025
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Roche Holding CHF 21.01B 10.84B Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
TG Therapeutics USD 142.08M 9.74M Dec/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
Vertex Pharmaceuticals USD 1.93B 89.1M Dec/2025
Xencor USD 81.86M 13.35M Dec/2025